Dr. Samuele Cazzamalli is giving a presentation entitled “DNA-Encoded Chemical Libraries for the Discovery of Highly Potent Tumor-Targeting Ligands and for the Development of Anti-Cancer Small Molecule Therapeutics”. Follow the...
Read moreDr. Samuele Cazzamalli is giving a presentation entitled “From DNA-Encoded Chemistry to anti-cancer Radio Ligand Therapeutics and Small Molecule-Drug Conjugates”.
Follow the link for more details
Management will provide an update on the industrial programs, including on the topline results from the Nidlegy™ Phase III trial presented at ASCO 2024. Please contact us at IR@philogen.com or...
Read moreProf. Dr. Axel Hauschild, on behalf of Philogen, is giving a presentation about the Phase III PIVOTAL study on May 31st, entitled “Phase 3 study (PIVOTAL) of neoadjuvant intralesional Daromun...
Read moreDr. Ettore Gilardoni (Head of Mass Spectrometry) will attend the 72nd ASMS conference in Anaheim (2-6 June 2024) and present a poster entitled: “Mass Spectrometry evaluation of glycosylation variants and...
Read moreDr. Andrea Galbiati is giving a presentation about Philochem’s FAP ligand platform on June 9th, entitled “Development of Multivalent OncoFAP Derivatives for the Tumor-Targeted Delivery of Theranostic Radionuclides”. Dr. Samuele...
Read more